A key aspect of genomic medicine is to make individualized clinical decisions from personal genomes. We developed a machine-learning framework to integrate personal genomes and electronic health record (EHR) data and used this framework to study abdominal aortic aneurysm (AAA), a prevalent irreversible cardiovascular disease with unclear etiology. Performing whole-genome sequencing on AAA patients and controls, we demonstrated its predictive precision solely from personal genomes. By modeling personal genomes with EHRs, this framework quantitatively assessed the effectiveness of adjusting personal lifestyles given personal genome baselines, demonstrating its utility as a personal health management tool. We showed that this new framework agnostically identified genetic components involved in AAA, which were subsequently validated in human aortic tissues and in murine models. Our study presents a new framework for disease genome analysis, which can be used for both health management and understanding the biological architecture of complex diseases.
INTRODUCTION
Many complex diseases have a strong genetic component (Manolio et al., 2009) ; however, one long-standing question has been whether a clinical test can be developed consisting of a simple genome scan (Snyder et al., 2009 ). Genome-wide association studies (GWAS) typically yield weak signals (McCarthy et al., 2008) , making them impractical for clinical use. More importantly, disease outcomes usually result from the combined effect of personal genomes and individualized lifestyles. This makes an integrative model highly desirable, where the model is capable of identifying different genomic propensities for a given disease among the general population, and also providing quantitative and actionable guidelines on lifestyle adjustment to minimize disease risk.
We aim to devise such a new analytic framework for complex human diseases. As a proof-of-principle, in this study, we targeted a prevalent cardiovascular disease, abdominal aortic aneurysm (AAA) because of its strong genetic component, unknown genetic underpinnings, robust associations between clinical outcomes and lifestyles, and readily available clinical information. AAA is a common, severe, and complex disease that ranks as the tenth leading cause of death in western countries and affects 3%-9% of the population over age 65 (Brangsch et al., 2017; Thompson et al., 2006) . It is hallmarked by irreversible dilation of the infrarenal aorta to a diameter of R30 mm and is accompanied by chronic inflammation, vascular smooth muscle cell apoptosis, extracellular matrix remodeling and degradation, and luminal thrombosis (Aggarwal et al., 2011; Nordon et al., 2011) . AAAs are asymptomatic as they grow, and clinical diagnosis is usually made at a late stage. Rupture of the aorta, the most common complication, has a mortality rate of 90% (Pearce et al., 2008) . Previous studies have associated personal lifestyles and several physiological parameters with AAA occurrence, such as smoking history and the cholesterol level (Golledge et al., 2007; Hobbs et al., 2003; Stackelberg et al., 2017) ; however, the genetic component in AAA is substantial with an estimated heritability of 70% (Wahlgren et al., 2010) . Therefore, identifying the genetic underpinnings of AAA will ultimately guide clinically actionable decisions for early diagnosis, monitoring, and intervention and provide mechanistic insights into this disease.
AAA exhibits significant mutational heterogeneity (Bown, 2014; Hinterseher et al., 2011) , preventing typical GWAS approaches from identifying robust and replicable at-risk loci (Bradley et al., 2016) . Over the past decades, we and many other laboratories have extensively studied this disease using human tissues and mouse models. However, current knowledge of its genetic underpinnings has not been sufficient to guide early screening of AAA in clinical practice. To gain a comprehensive view of the mutational landscape underlying the disease, we, for the first time, performed high-coverage whole-genome sequencing (WGS) for AAA patients and controls and devised a novel machine-learning framework to directly map genomic variants onto disease traits ( Figure 1A ). This analytical framework, HEAL (hierarchical estimate from agnostic learning), was constructed using machine learning and network analysis techniques, hierarchically modeling individual mutation effects, and simultaneously identified the aggregated mutational burden on genes and ablated biological pathways. It also integrates personal genomes with electronic health record (EHR) data to derive insights into disease etiology, clinical prognosis, and potential interventions. Such a data-driven strategy is agnostic by nature, presuming no pre-existing knowledge nor requiring a large number of samples. With rigorous testing and experimental validation, we showed that HEAL not only identified disease-associated components in AAA by aggregated learning from population genomes but also accurately predicted disease We studied the genetic and non-genetic factors of abdominal aortic aneurysm (AAA) by means of combining whole-genome sequencing and electronic health records (EHRs) in AAA diseased and non-diseased individuals whose disease status were confirmed by imaging technologies. A new machine learning algorithm called HEAL was devised to distinguish diseased individuals from non-diseased, and the derived model was applied to predict AAA outcomes in a new group of individuals. The model produced a list of genes with weighted contributions to the disease, which were subsequently mapped on the protein-protein interaction network to reveal the AAA-associated modules. Gene expression of these modules was confirmed by transcriptome studies in human aorta biopsies from AAA patients, as well as animal models of AAA. (B) Through genome analysis, the HEAL algorithm analyzed genomic variation at the levels of single nucleotide variation (SNV), gene, network, and aggregating and expanding genomic information at higher functional levels. See also Figures S1 and S2 and Tables S1 and S2. status purely from personal genomes. When combined with personal EHR data (e.g., lifestyles and physiological measurements), the predictive power of HEAL is further increased, reaching a level similar to or better than many existing clinical screening tests. Our study suggests that HEAL could be potentially developed into a clinically actionable test for early screening of AAA. By simultaneously modeling individual genomes and personal EHRs, HEAL revealed the interplay between the personal genome baseline and individual lifestyles underlying AAA predisposition, demonstrating its potential as a highly personalized health management tool. Overall, our study has significantly improved our understanding of the molecular etiology of AAA. More importantly, as envisioned for precision medicine, for the first time we provide proof-of-principle for a general analytical framework that has simultaneously achieved clinical prognosis and disease gene identification from personal genomes.
RESULTS
Whole-Genome Sequencing of AAA Samples Individuals with an abdominal aortic diameter R30 mm were considered AAA-positive (Moxon et al., 2010) and those < 30 mm were considered AAA-negative. AAAs secondary to connective tissue diseases were not considered. We identified 313 AAA cases and 161 controls enrolled in our clinical practice at VA Palo Alto Healthcare System, Stanford University and Kaiser Permanente (Betz et al., 2015; Myers et al., 2014) . We confirmed their AAA status by re-visiting their clinical records for abdominal aortic diameters (Table S1 ). Integration of participant EHR data was derived from the clinical records as well as patient interviews, including individuals' various physiological measurements and lifestyles upon their last clinical visit before the initiation of the project. This resource provided a unique opportunity to enrich our disease genome analysis as described below.
We performed WGS on whole blood samples to an average genome coverage of 503, resulting in 48 terabytes of aligned reads. We chose WGS over exome-sequencing because it provides more uniform coverage, better genotype quality, and fewer false-positive calls (Lelieveld et al., 2015) . To process this large amount of sequencing data and perform rigorous quality control and validation, we developed a cloud-based analytical pipeline (Pan et al., 2017) . The resulting genome-wide mutation profiles were subsequently subjected to population admixture analysis, which retained 268 cases and 133 controls for further analysis with an admixture component for European ancestry >90% (Figure S1 ; Table S2 ). With this pipeline, we identified 23,750,363 high-quality single nucleotide variations (SNVs). We excluded short insertion and deletions (indels) given their lower confidence (Zook et al., 2014) .
We first performed GWAS to model AAA dichotomous outcomes with ethnic disparities corrected by the above population admixture analysis. No single genomic locus reached statistical significance at the threshold of p = 5eÀ8 ( Figure S2 ). A lack of GWAS signal is typically attributed to two possible scenarios: (1) rare variants, which cannot be effectively captured by a GWAS that is designed for common variants (Cirulli and Goldstein, 2010) , and (2) locus heterogeneity, where different individuals carry distinct sets of pathogenic mutations (McClellan and King, 2010) . In either situation, a large sample size is required, where at-risk loci could be proportionally enriched in cases relative to controls to reach statistical significance.
Because rare variants have been thought to have larger effect sizes (Auer and Lettre, 2015; Cirulli and Goldstein, 2010 ), we examined rare variants in AAA, and to overcome the challenge of locus heterogeneity, we constructed a machine-learning model, as opposed to association models based on statistical tests at each individual locus. Our earlier studies showed that for a well-defined clinical phenotype, the seemingly heterogeneous mutations may converge onto a common set of pathways (Li et al., 2014 (Li et al., , 2015 . In other words, it is not a common set of mutations that are prevalent in case samples (the typical GWAS framework), but rather a common set of gene functions that are more likely to be ablated among patients (i.e., common ablated pathways). In this ''mutational convergence'' framework, the task of GWAS for identifying a handful of significant mutations out of millions of SNVs is reduced to finding a subset from $20,000 human genes whose mutational pattern can distinguish cases from controls. In practice, by reducing the search space from millions of mutations down to $20,000 genes, the sample size requirement is greatly lowered. Given the insignificant signal from GWAS, we examined whether we could identify a minimal subset of genes across the genome, whose combinatorial patterns of rare variants effectively predicts AAA status.
HEAL: An Agonistic System for Disease Genome Analysis
We developed HEAL to identify AAA-associated genetic components. The overall design of HEAL is shown in Figure 1B . At the individual SNV level, the algorithm first examined the potential clinical relevance of each individual mutation by annotating its functional consequences, population frequency, and the predicted pathogenicity. To overcome mutational heterogeneity, HEAL constructed a machine-learning framework to agnostically identify a subset of genes showing distinct mutational patterns in cases relative to controls and used this pattern to predict clinical outcomes from personal genomes. To gain further insights into disease etiology, HEAL mapped the identified genes onto biological networks to reveal a complete picture of the diseaseassociated pathways. As hierarchically modeled, HEAL analyzes consequences at the mutation level, predicts disease outcome at the gene level, and unravels disease etiology at the network level ( Figure 1B) . Moreover, HEAL can be further expanded to incorporate personal EHRs to complement genomic investigations, which will be detailed below.
Among millions of SNVs identified, we considered the 66,047 rare nonsynonymous mutations (missense, nonsense, and those affecting splice sites) that were not present in the European populations analyzed in the 1000 Genomes Project (Sudmant et al., 2015) . For each gene, we quantified its mutation burden in each study participant based on the cumulative effects of deleterious nonsynonymous mutations. HEAL then represented each of the 401 study participants (268 cases and 133 controls, Figure 1B ) with the mutational burden for each of the entire collection of human genes. We trained a penalized linear classification model to predict the AAA status for each individual, where the penalty term of the classification model served to identify the minimal set of the most distinguishing features (i.e., genes with aberrant mutational burden in cases) for AAA prediction ( Figure S3A ). It is important to note that this sparse learning technique effectively avoids potential overfitting in model construction (Tibshirani, 2011) , which is further evidenced by cross-validation procedures shown below.
HEAL assigned non-zero weights to 149 genes, and identified a minimal set of 60 genes (Table S3 ) whose mutational burden was elevated in cases relative to controls. Note that the entire learning process in HEAL was agnostic, only guided by classification accuracy. Therefore, without injecting our prior knowledge, the identified genetic components reflect their natural organization in AAA. We performed 10-fold cross-validation 1,000 times to eliminate potential randomness in splitting training and testing samples, where each study participant was blindly tested 1,000 times using different combinations of training samples of the same size (excluding testing subjects when training) (Table  S4) . Averaging these blind test scores over the 1,000 simulations demonstrated the predictability of AAA status based on the selected genes with an AUROC (area under receiver operating characteristic curve) = 0.69 (Figure 2A) , and the distribution of AUROCs for the 1,000 iterated cross-validations is shown in Figure S3B .
We also closely examined EHRs of these study participants, including their personal lifestyle surveys and lifestyle-associated physiological measurements during their last clinical visit before the initiation of this project. These included sex, age, status as a regular smoker, heart rate, waist-to-hip ratio, insulin level, fasting glucose level, lipid profiles, and several other factors. We constructed a similar machine learning model and found that the EHR information could effectively distinguish AAA patients from non-AAA individuals with an AUROC of 0.775 from the same cross-validation procedures, higher than the genomebased model at AUROC = 0.69 ( Figure 2A ; Table S4 ). It is important to note that the higher AUROC from EHRs was expected given known associations with AAA of these physiological and lifestyle elements (Golledge et al., 2007; Hobbs et al., 2003; Stackelberg et al., 2017) . However, the prediction achieved by the genome-based model was remarkable, especially given the unclear molecular and genetic basis of this complex disease.
Integrating the EHR information with our genome-wide genetic prediction generated a significant increase in the predictive power to AUROC = 0.80 ( Figure 2A ; Table S4 ), demonstrating the complementarity of personal genomes and individual lifestyles in predicting disease outcomes. This performance increase over the EHR-based model was significant, as determined by the 1,000 iterated cross-validations (p < 1eÀ3). The resulting true-positives (TP), true-negatives (TN), false-positives (FP), and false-negatives (FN) in the integrated model are illustrated in Figure 2B , where prediction scores for each individual were averaged over the 1,000 cross-validations thresholded at 0.5 for predicted AAA outcomes.
We also examined individual cases with the integrated model, as exemplified by Figures 2C-2F: a study participant that received a low AAA prediction score (0.16) indeed had a small abdominal aortic diameter (20.1 mm) from ultrasound scan (Figure 2C) , whereas another individual with a highly dilated abdominal aorta (51.2 mm) from a CT (computed tomography) scan was scored highly by HEAL (prediction score 0.68, Figure 2F ). Notably, two individuals with marginally significant abdominal aortic diameters (31.2 and 30.0 mm in Figures 2D and 2E , respectively, from ultrasound scans) were also scored with marginal AAA probabilities by HEAL (prediction scores of 0.55 and 0.43 in Figures 2D and 2E , respectively), demonstrating that the clinical definition of AAA had indeed been learned by HEAL. Taken together, the genome-based model in HEAL identifies the genome baseline for an individual to develop AAA, and the combined genomics and EHR model in HEAL more accurately predicted the risk, representing a post-probability incorporating genomics, lifestyle, and physiological factors and their interactions.
A Potential Clinically Applicable Test for AAA by Integrating Personal Genomes with EHR Data
Because both genome-and EHR-based models predicted AAA status, we asked whether the two models predicted AAA from different mechanisms or from a convergent base (i.e., some EHR phenotypes could be captured by the genome-based model trained for AAA). We performed the same analysis as described above, where we regressed (for continuous traits) or classified (for dichotomous traits) each EHR phenotype using the variants in the genes best predicting AAA, but found little correlation between the genetic and phenotypic variances (R 2 < 0.1). This observation indicated a direct mapping from personal genomes to AAA status, not through other EHR traits. Because combining EHR and genome information increased prediction accuracy, we hypothesized that false predictions from personal genomes could be captured by EHR-based predictions. Therefore, we first identified false-positives and falsenegatives from personal genome predictions, and asked how many of them were correctly captured by the EHR-based predictions. To determine statistical significance, we randomly permuted the AAA labels for EHR predictions 1,000 times and observed that the false-negatives from genome prediction were indeed enriched for the true-positive predictions in the EHR model (p < 1eÀ3, group 1; Figure S3C ), and the enrichment was also evident for the genome false-positives in the EHR truenegatives (p < 1eÀ3, group 2; Figure S3C ).
We next examined the false-positive and false-negative rates achieved by the genome-and EHR-based models, which could guide clinical practice. Interestingly, the genome-based model had an overall comparable or lower false-negative rate (better performance in capturing real patients) than the EHR model across all possible prediction thresholds ( Figure 2G ) but with a relatively higher false-positive rate ( Figure 2H ). The corresponding true-positive, true-negative, false-positive, and false-negative rates at each prediction threshold are displayed in Figures 2I and 2J. In practice, the choice of a prediction threshold should be based on the clinical demand by trading-off the false-positive and false-negative rates. Beyond the analytical comparison, from a clinical perspective, it is important to note that the EHR information reflects the current status of an individual, whose value is limited for disease assessment at a very early stage. However, the genome-based model will allow an early assessment of this disease for personal genome baselines, which is critical given the irreversible progression of the disease, and such an early assessment tool is lacking and strongly desired in clinical practice. Given its low false-negative rate and relatively higher false-positive rate, the genome-based model has the potential to be deployed as an early screening tool for AAA, and the false-positive calls can be easily complemented by the inexpensive and non-invasive ultrasound follow-ups.
To demonstrate the predictive strength and clinical utility of HEAL, we performed 1,000 sets of blind testing using the 10-fold cross-validation procedure (as described above). We determined the mean sensitivity (SN) and specificity (SP) of the genome-based model and the integrated model by aggregating genome and EHR information. Both models achieved similar or better performance compared with many widely used clinical screening tests for different diseases ( Figure 3A ) (Maxim et al., 2014) , including gestational diabetes, significant coronary stenosis, and cytology-based cervical cancer screening, indicating that our prediction test has potential clinical applicability.
The Interplay between Personal Genomes and Individual Lifestyles For each individual, HEAL accurately predicted his/her AAA risk using personal genome and EHR data (Figure 2 ). On the other hand, for the same individual with newly adopted lifestyles resulting in physiological changes (e.g., from a high cholesterol to a low cholesterol diet), HEAL can immediately update his/her AAA risk upon corresponding changes conditioned on the person's genome baseline. This allows us to further investigate the interplay between personal genomes and lifestyles underlying disease predisposition. Among many factors, we used plasma high-density lipoprotein (HDL) cholesterol level for the purpose of proof-of-principle given the unequivocal association between high HDL level and low AAA occurrence (Torsney et al., 2012) . We performed a simulation study on this AAA cohort by in silico decreasing or increasing one's plasma HDL level, followed by a re-estimate of the associated AAA risk by HEAL conditioned on one's personal genome. For each individual, their current AAA risk was derived from the integrated model by aggregating personal genomes and EHRs; we then stepwise increased or decreased their HDL levels from their EHR-recorded values. Figure 3B displays the risk profiles of individuals upon altering their plasma HDL levels. Overall, as expected, the HDL level was negatively correlated with AAA risk scored by HEAL. However, for a subset of individuals (groups A and D), their AAA status (AAA-positive for group A and AAA-negative for group D) was largely invariant upon HDL changes, corresponding to The interplay between personal genomes and individual lifestyles. HEAL predicts the risk for developing AAA by stepwise varying plasma highdensity lipoprotein (HDL) cholesterol levels. On y axis, the current status line indicates the prediction score from individual genomes and EHR data upon the latest clinical visits (false predictions were not considered here). The HDL level of each participant (column) was then in silico increased or decreased, followed by a recalculation of one's AAA prediction score using HEAL. In this simulation, the population range (L) of the HDL of this study cohort was first determined, which is the difference between the population maximum and minimum. The HDL value of each person was then increased or decreased by 25% of L progressively until reaching population maximum (+, rows above the current status line) or population minimum (À, rows below the current status line), respectively. The numbers from 1 to 4 refer to an increase or decrease from 25% to 100%. See also Figure S2. their extremely high or low genome baselines (prediction scores from the genome-based model, bottom panel, Figure 3B ). In contrast, for most individuals, their AAA risk was sensitive to HDL changes: for these cases, an HDL increase could bring the predicted AAA risk down to the prediction threshold (risk score at 0.5, group B), whereas for controls, an HDL reduction could result in a positive AAA prediction above the prediction score threshold of 0.5 (group C). Taken together, these analyses highlight the importance of personalized health management by integrating one's genome baseline and lifestyle/physiological parameters and demonstrate the applicability of HEAL as a potential tool for this purpose.
Identifying the Molecular Basis of AAA Simultaneously with prediction of disease risk, HEAL agnostically identifies at-risk loci for the disease. 60 genes were agnostically and automatically selected ( Figure S3D ; Table S3 ), whose increased mutational burden in cases contributed to prediction accuracy. Close examination of the 60 machineidentified genes (HEAL genes) confirmed their increased mutational burden for deleterious rare variants in cases relative to controls (p = 2.47eÀ6; Figure 4A ). We then examined whether these machine-identified genes could help reveal unbiased sources of molecular etiology in this disease. The 60 HEAL genes (Table S3) showed an overall enrichment for immunerelated functions, such as interferon-gamma-mediated signaling (false discovery rate [FDR] = 0.07), MHC class II receptor activity (FDR = 1.6eÀ4), and T cell co-stimulation (FDR = 0.07), consistent with the known significant immunological/inflammatory components of AAA pathophysiology (Kuivaniemi et al., 2008) .
To better understand the molecular function of the identified genes, we compared their gene expression in human aortic specimens. Tissue samples were obtained from 20 patients with small AAAs (30-55 mm), 29 patients with large AAAs (>55 mm), and 10 control aortic specimens (Biros et al., 2015) . We computed the fold change for each human gene in small AAAs and large AAAs, respectively, relative to control subjects. Interestingly, the 60 HEAL genes displayed an overall significant upregulation in both small AAAs ( Figure 4B , p = 8.90eÀ4, Wilcoxon rank-sum test) and large AAA specimens ( Figure 4B , p = 1.9eÀ2, Wilcoxon rank-sum test). This comparison suggests a potential mechanism in AAA, where genetic alterations converge onto a common set of pathways, either by mutations or by altered gene expression.
To determine the functional context of the 60 HEAL genes, we mapped them onto the high-quality human protein-protein interaction (PPI) network, encompassing 16,083 proteins and 217,695 experimentally derived, non-redundant, pairwise interactions (Chatr-Aryamontri et al., 2017) . The high quality of these Tables S3 and S5. protein interactions has been previously validated in an independent study (Li et al., 2014) . We computed shortest path distances (SPD) on the network for any pair of the HEAL genes as a proxy for their functional similarities, but the 60 genes did not exhibit reduced SPDs relative to any randomly selected protein pairs on the network (p > 0.05, Wilcoxon rank-sum test). This observation suggests that the 60 HEAL genes are not topologically clustered, but are likely distributed across several biological pathways underlying the disease. Therefore, multiple functional modules likely contribute to AAA, rather than only a few tightly clustered functional components, which is consistent with published pathway data (Spin et al., 2011) .
Functional Modules in AAA
We seeded the 60 HEAL genes into the protein interaction network and devised a new framework to identify proteins tightly clustered with these HEAL genes as topological modules. We performed diffusion component analysis (Cho et al., 2016) on the network and identified 40 tightly clustered topological modules encompassing the 60 HEAL genes ( Figure 4C ; Table S5 ). Gene ontology confirmed the functional coherence of the proteins in each module ( Figure 4C ), such as significant enrichment for blood vessel development in module M577 (FDR = 2.3eÀ8) and blood circulation in module M438 (FDR = 4.8eÀ3).
To interrogate the pathogenic roles of the modules in AAA, we studied their expression in human AAA samples (Biros et al., 2015) as described above ( Figure 5A ). Interestingly, in either small or large AAA cohorts, the same set of seven modules exhibited significant dysregulation, including the upregulation of module M438 (regulation of blood circulation) ( Figure 5B , FDR = 1.2eÀ3 for small AAA and FDR = 2.7eÀ3 for large AAA). We particularly noted that module M438 was strongly associated with abnormal systemic arterial blood pressure and dilated cardiomyopathy phenotypes according to OMIM annotations (FDRs <0.05).
We next examined whether the identified modules might be involved in AAA development in murine models. In one well-established model, angiotensin II (AngII) is infused via implantable pumps into apolipoprotein E-deficient (ApoE À/À ) mice, which then develop suprarenal AAAs, exhibiting predictable resultant histopathology that shares many features with human disease (Daugherty et al., 2000) . We have previously published whole genome microarray-based transcriptional profiling of aortic tissue from the AngII/ApoE À/À model over a 28-day time course
(Spin et al., 2011). These studies suggested (based on pathway analysis), that day 7 represents a critical period in AAA development in this model, which is followed by progressively less differential gene regulation over time (Spin et al., 2011) . We considered one-to-one unambiguous mouse orthologs of the modular genes noted above and identified five modules exhibiting significant expression alterations in developing AAA phenotypes at day 7 in the murine model ( Figure 5C ), including significant upregulation of module M577 (FDR = 0.05, Wilcoxon rank-sum test) and module M725 (FDR = 4.6eÀ3, Wilcoxon rank-sum test) for the collagen metabolic process (FDR = 0.01, Wilcoxon ranksum test). For module M577, the corresponding mouse mutants showed aneurysm phenotypes according to Mouse Genome Informatics (MGI) (FDR = 1.96eÀ6, MGI:MP0003279, Figure 5D ); (D) Module M577 is highlighted in red for network visualization. All the modules shown displayed significant expression alterations compared with the transcriptome background at false discovery rates (FDRs) <0.1. In (A) and (C), the red dashed line marks the baseline of fold changes at the transcriptomic background; 2-fold change thresholds were marked by black dashed lines of 0.5 and 2; extreme outliers were condensed between the gray lines. See also Figure S4 .
similarly module M725 is associated with collagen-associated function, whose role in AAA was previously established (Menashi et al., 1987) . Unsurprisingly, by day 28, only module M698 for ubiquinone metabolic process remained significant (FDR <0.05, Wilcoxon rank-sum test, see Discussion).
Another established murine AAA model that mimics many human AAA features involves localized infusion of porcine pancreatic elastase (PPE) into the infrarenal aorta of C57BL/6 mice (Azuma et al., 2009) . Our previous studies have found that PPEinduced aortic AAA size also differs significantly in size from those of sham (saline-infused) animals by day 7, and transcriptional profiling at that time point identifies numerous up-and downregulated genes . With the same procedures described above for aged mice, module M698 and M704 showed significance in the PPE data ( Figure S4 , FDR <0.1, Wilcoxon rank-sum test), where M698 for the ubiquinone metabolic process consistently showed significance as observed in human tissues and the AngII/ApoE À/À model, and module M704 for cellcell communication (FDR = 1.8eÀ2) was specific to the PPE model. Taken together, these comparisons involving human tissues and mouse models collectively demonstrate the pervasive involvement of the HEAL modules in AAA. It should be noted that the human samples described above likely represent endstage disease, while the animal model studies illustrate the dynamic nature of disease progression, highlighting the evolving involvement of multiple modular genes/pathways over time.
DISCUSSION
In this study, we performed WGS for individuals with AAA and, for the first time, revealed the global mutational landscape across AAA genomes. We used AAA as a proof-of-principle and developed an entirely new analytical framework, HEAL, to identify the genetic components in this disease. HEAL identified 60 key genes with increased mutational burden in AAA cases, and implicated 40 distinct functional modules underlying the molecular etiology of disease, which were experimentally validated using human aortic tissues and experimental mouse models. Overall, our study significantly advances current understanding of AAA, one of the most prevalent cardiovascular conditions in the aged population (Brangsch et al., 2017; Thompson et al., 2006) . More importantly, we present a new paradigm for disease genome analysis that is driven by machine learning and network modeling techniques, thus opening a new avenue for future research in genomic medicine. HEAL is an integrative framework built on two synergistic components: ''hierarchically estimating'' and ''agnostically learning'' ( Figure 1B) . Hierarchically estimating identifies pathogenic variants, aggregate mutations over gene loci, and detects diseaseassociated pathways, which are common practice in disease genome analysis. Agnostically learning is new, is based on the sparse learning technique, and has simultaneously achieved disease prediction and disease gene identification from personal genomes. Two key elements underlie the success of HEAL. First, we considered rare variants by removing variants identified from the 1000 Genomes. This practice is to deplete neutral variants so that the disease-associated variants will be enriched in cases relative to controls. Second, for the retained rare variants, we developed a new machine learning strategy to maximize the distinction between cases and controls using the combinatorial mutation pattern in a minimal set of genes. The predictive power achieved by HEAL thus provides solid evidence for the ''common diseases, rare variants'' model for AAA, which likely explains the weak signals from previous AAA GWAS for common variants (odds ratio = $1.2) (Jones et al., 2017) . As a control experiment, the disease could not be predicted when training the same machine learning model based only on the 1000 Genomes variants across all frequency bins ( Figure S5 ). Worthy of note, although subjects in 1000 Genomes are presumably healthy, a few could develop AAA at a later stage of their life. As such, our current model excluded some useful information by removing 1000 Genomes variants, and identifying these individuals could help further increase the existing prediction accuracy.
The HEAL framework is flexible in that its predictive power could be further enhanced by integrating personal genomes with individual EHR information given the complementarity between the two models ( Figure S3C ). However, predictions from personal genomes for the first time makes possible early assessment of this disease, and will facilitate the development of early intervention strategies (i.e., improving HDL levels) based on one's genome baseline. Therefore, in addition to a clinical test for early assessment, HEAL could also be deployed as a tool for personalized health management and disease intervention by integrating one's personal genome and lifestyle. As demonstrated in Figure 3B , different individuals have different responses to lifestyle changes, reflecting differential disease susceptibility from personal genomes. The highly individualistic genome baselines thus require personally tailored lifestyles to best reduce disease-risk, which now can be quantitatively calculated by HEAL.
We identified 60 genes with increased mutational burden in AAA cases, leading to revelation of 40 functional modules in this disease ( Figure 4C ). These modules, encompassing genes in immune response, blood vessel development, blood circulation, and cell-cell communication, etc., support earlier studies on the roles of angiogenesis and the immunological component in this disease (Kuivaniemi et al., 2008; Spin et al., 2011; Tedesco et al., 2009 ), but more importantly, they have expanded our view of the molecular basis underlying AAA, with novel pathways now implicated. We validated these pathways using human aortic tissues and two distinct mouse models, which not only served to confirm their involvement in AAA but also demonstrated that the pathogenic mutations in our sequencing study and the differentially expressed genes in the validation experiments in fact converge onto a set of common pathways. Our results imply that treatments aimed at regulating these modules may have disproportionately beneficial impact on AAA development and open new avenues for future studies.
Several novel pathways uncovered in this study are worth highlighting. Module M438 (Figure 5B ), centered on the cardiac protein SNTA1 (syntrophin alpha 1), was highly enriched for blood circulation functions, suggesting connections between cardiac function, blood pressure regulation, and development of AAA. Close examination of module M577 reveals an enrichment of collagen proteins ( Figure 5D ), which tightly interact with two PDGF (platelet-derived growth factor) proteins (PDGFA and PDGFB). These regulators of SMC (smooth muscle cell) proliferation and angiogenesis are well established mediators in AAA pathophysiology (Kanazawa et al., 2005) . The identification and validation of the ubiquinone metabolism module (M698) for AAA is particularly intriguing, as this module showed consistent downregulation in multiple AAA-associated conditions ( Figures  5A, 5C, and S4) . The primary role of ubiquinone/CoQ (coenzyme Q10) is as a redox-active component of electron transport participating in mitochondrial oxidative phosphorylation (Stefely and Pagliarini, 2017) . It acts both as an electron transporter and a free-radical scavenging antioxidant. Mitochondrial function plays a key role in smooth muscle cell phenotype (Deuse et al., 2014) . Ubiquinone levels (and those of other antioxidants) decrease with increasing abdominal aortic aneurysm size in humans, suggesting a role for oxidative stress in AAA and a potential therapeutic role for antioxidants (Pincemail et al., 2012) . Further, metabolic oxidative phosphorylation in aortic tissue is significantly downregulated both in human AAA (Biros et al., 2015) and murine AAA models (Spin et al., 2011) . Oxidative stress is a crucial element in vascular inflammation, and reactive oxygen species (ROS) have long been associated with AAA formation in animal models and in humans (Bolton et al., 2000) . Conceivably, genetic dysregulation of ubiquinone biosynthesis and processing might alter the physiologic response to inflammation and lead to metabolic dysregulation, predisposing to AAA development. While the therapeutic use of CoQ has been controversial, it is recognized that supplementation might decrease vascular inflammation and oxidative stress (Herná ndez-Camacho et al., 2018) . Our data would suggest that it may have a role in the treatment of AAA. Taken together, our genomic and transcriptomic analysis provides a global view of the components of the disease; however, their mechanistic contribution and pathophysiological significance require follow-up experiments and clinical investigations to determine.
In this study, HEAL predicts disease status purely from exonic SNVs, reaching AUC of 0.69 (Figure 2A ). This observation suggests substantial contribution to AAA from exonic SNVs. When incorporating non-coding variants in HEAL, its predictive power likely will be further enhanced. Moreover, in this study, we excluded indels and copy-number variants (CNVs) from our analysis due to technical reasons. These variant types, together with SNVs examined here, constitute the genetic basis of AAA. Therefore, the predictive power of HEAL in this study is an underestimate from personal genomes. In conclusion, using AAA as a proof-of-principle, we demonstrated the utility of a new framework, HEAL, which simultaneously identifies disease components and distinguishes cases from controls based on personal genomes. The HEAL framework is potentially applicable to many complex diseases, and our overall approach is expected to be valuable in developing clinical tests that incorporate personal genome sequences into disease-risk prediction.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS

Human subjects
The study protocols were approved by the IRB committee at Stanford University. A total of 474 study subjects, all adults self-reported as Europeans, were recruited and consented in written form through three local hospitals: VAPAHCS, Stanford Hospitals and Clinics, and Kaiser Permanente. To best reveal the molecular basis of AAA, control subjects were recruited that best matched EHR phenotypes of the case subjects. Overall, the detailed patient recruitment procedures have been described in an earlier study (Betz et al., 2015; Myers et al., 2014) . Study subjects were all de-identified and assigned with a machine-generated ID for sequencing, which were used throughout the project. Information of sex, age, and aortic diameters of study participants is provided in Table S1 . This study included both male and female subjects; however, the genomic analysis in this study only identified autosomal variants associated with this disease; therefore sex distribution did not affect our genomic analysis.
METHOD DETAILS
DNA preparation and sequencing Blood was drawn in a 10 mL Vacutainer collection tube (BD, Franklin Lakes, NJ) containing EDTA as the anticoagulant. Buffycoat was collected and transferred immediately into À80 C freezer. DNA was extracted using Epicenter MasterPure DNA purification kit (cat# MCD85201) and the manufacturer's protocol was followed. DNA concentration was measured by Nano Drop and Qubit fluorometer and stored under À20 C till use. DNA was sent to Illumina, Inc (San Diego, CA) for whole genome sequencing. Sequencing library preparation followed standard Illumina protocol, with the median insert size of 250 bp. Sequencing was then performed using the 101 base-pair pair-end reversible terminator massively parallel sequencing on the HiSeq 2000 instrument.
Read alignment and variant calling
Variant calling and data quality control steps were performed using the methods we developed on Google Cloud Platform (Pan et al., 2017) . Variant calling followed the best practices guideline by Genome Analysis Toolkit (GATK). Briefly, Reads were aligned using BWA-MEM v-0.7.10 to decoy human reference genome hs37d5. PCR duplicates were identified by Picard tools v-1.117. Local realignment around INDELs was performed by GATK v3.3 (referred to as GATK in the following description), in which realignment targets were first generated by RealignerTargetCreator and then the actual local realignment by Indelrealigner. Subsequently, base qualities were recalibrated by the Printreads function in GATK by observing the behavior of those bases reported in dbSNP137. Single nucleotide variation (SNV), short insertion and deletion (INDELs) and reference bases were called by the HaplotypeCaller in GATK. Variant quality score recalibration (VQSR) was performed by VariantRecalibrator in GATK with the following annotations: quality by depth, mapping quality rank sum, read position rank sum, Fisher strand, coverage, and haplotype score. The training datasets for SNVs were HapMap3, 1000 Genomes Phase I genotypes presented in Omni2.5 array and dbSNP135; and the following training dataset for indels was a curated set of indels in a previous publication (Mills et al., 2011) .
Data quality control
To guarantee high quality of the sequencing data, we performed numerous quality control procedures using methods we previously developed on Google Cloud Platform (Pan et al., 2017) , with the major procedures outlined below.
On the sample level, we (1) performed principal component analysis among all samples and found no batch effect among the different DNA library preparations; (2) compared the genotypes between sequencing data and SNP array data and found all genomes had high concordance; (3) inferred the sex based on heterozygous counts on chromosome X and tagged 6 samples that did not have matching self-reported sex; (4) computed inbreeding coefficient to infer family relationship, and tagged 6 genomes that resided more than 3 standard deviation from the mean; (5) computed identify-by-state as a proxy for genome similarity and found no crosscontamination; (6) assessed missing calls for each genome and found all genomes had minimal missing calls when considering all called positions; (7) assessed the distribution of singleton calls in every genome and tagged 2 genomes that resided more than 3 standard deviation from the mean; (8) assessed the distribution of heterozygous calls in every genome and tagged 5 genomes that resided more than 3 standard deviation from the mean; (9) performed population admixture analysis using the ADMIXURE program referencing European, Asian and African genomes in the 1000 Genomes dataset (Phase 3) and tagged 69 genomes with < 90% European ancestry. Subsequently, all tagged genomes were removed from the downstream analysis. A summary of the sample-level QC was provided Table S2 .
On the variant level, we (1) tagged variants on blacklisted regions, compiled by the ENCODE Project Consortium (2012), (2) tagged heterozygous haplotypes, i.e., heterozygous call on chromosome X in male genomes, and (3) tagged variants identified other than ''PASS,'' such as ''low quality,'' ''tranche99.0-99.5,'' by VQSR in GATK. All tagged variants were not included in the downstream analysis.
Genome-wide association studies
We performed standard genome-wide association studies (GWAS) analysis for all the SNVs detected in the whole genome sequencing by using PLINK (version 1.07). In particular, we used the following criteria to include SNVs for GWAS analysis: missing rate per person less than 0.1, allele frequency greater than 0.01, missing rate per SNV less than 0.1, and Hardy-Weinberg Equilibrium greater than 0.001. The genomic inflation factor was 1.04875. We considered genome-wide significance at p = 5e-8 ( Figure S3 ).
HEAL design and implementation
Identifying rare variants Among millions of SNVs from our whole genome sequencing, we considered only rare nonsynonymous mutations that were not identified in the European populations in the 1000 Genomes Project phase 3 dataset, yielding 66,047 nonsynonymous SNVs. ANNOVAR (2016Feb01) (Wang et al., 2010) was used to annotate the SNVs based on the RefSeq genes defined in the human genome (hg19). Quantifying gene mutation burden To estimate the mutation burden per gene based on the rare SNVs, we first predicted the deleteriousness effect of each nonsynonymous SNV based on three algorithms that have best performance among many other methods, namely VEST3, MetaLR and M-CAP, which were internally computed by ANNOVAR. The prediction scores were then averaged for overall assessment of deleteriousness of individual nonsynonymous SNVs. Next, we considered the cumulative effects of nonsynonymous SNVs for each gene. We considered 17,443 protein coding genes with SNV annotations, and for each gene i (i = 1, ., 17 443) of the nth sample, we calculated its mutation burden as
in which m in is the number of rare SNVs in gene i of sample n, and s ijn is the average deleteriousness score for SNV j of sample n. We performed the above procedure for AAA cases and controls respectively. As a result, each individual was represented by a feature vector of 17,443 dimensions, with each dimension as the mutational burden for one gene, i.e.,
where x n ∈ R
17443
. A regularized linear model for genome-based prediction In the machine learning framework, the mutation burden matrix across individuals was trained to predict AAA outcome. In brief, the cohort in our study can be represented by variable pairs {x n ,y n }'s (n = 1, ., 401), in which x n is given by Equation (2), and y n represents the label for ''case'' or ''control,'' i.e., y n = 1 indicates that the nth sample is ''case,'' and y n = 0 indicates it is ''control.'' To model the additive effect of gene mutation burden on disease risk, we first introduced coefficients w i 's to individual genes, measuring the contribution from mutation burden of corresponding genes to AAA status. Specifically, given the gene mutation burden profile x n for the nth sample, its probability of being AAA positive can be modeled as
where s(•) is the sigmoid function. Next, we identified the optimal coefficient vector w that helped achieve the maximum consistency between the model probabilities and the observations for the cohort. Indeed, here we solved the following problem,
in which the optimization objective function was the average cross-entropy of the sample set, which, in fact, could be formulated into a logistic regression problem. However, the main challenge here was that we had a large number of features (17,443 genes) compared with a relatively small number of training samples (# of individuals, N = 401), which would result in the overfitting problem.
In this study, we adopted a parsimonious/sparse structure in the solution, in which we aimed to identify a minimum number of genes/ features to best explain the observations. For this purpose, we introduced an L 1 penalty term into Problem (4), i.e.,
in which the L 1 norm induced a sparse structure, the parameter l tuned the level of sparsity of the solution and was set to 1.5 in this study. In fact, Problem (5) can be treated as the logistic regression version of LASSO, a commonly used sparse learning technique in statistics and machine learning (Tibshirani, 2011) . Based on the optimal w in Problem (5) and Equation (3), we were able to predict the AAA status solely from personal genomes. We used Scikit-learn to implement our method and solve Problem (5). The machine learning model for EHR-based prediction In addition to the genome-based model described above, we also developed an EHR-based logistic regression model to investigate the contribution of EHR phenotypes to AAA status, In this EHR-based model, we used 14 phenotypes including lifestyles and physiological measurements, see the main text for details. Logistic regression was also implemented by Scikit-learn.
Integrating the genome-and EHR-based models We integrated both genome-and EHR-based models by averaging their respective prediction scores, which can further increase our prediction performance (Figure 2A ).
Network analysis
The human protein interaction network We downloaded high-quality human protein-protein interaction network (PPI) from BioGRID (version 3.4.143), involving 16,083 proteins and 217,695 experimentally derived, non-redundant, pairwise interactions. Identifying functional modules in AAA To identify physical pathways in AAA, we seeded the 60 genes identified by HEAL in the human protein-protein interaction network and performed topological analysis to identify the modular structures in AAA. We first mapped individual proteins in the network onto a low-dimensional space based on their topological characteristics in the network, and the low-dimensional representation of each protein was derived by diffusion component analysis (DCA). This approach is to embed nodes in a network into a low-dimensional feature space, which has achieved the best performance for various biological problems compared with many other methods (Cho et al., 2016) . We then implemented K-means clustering algorithm and identified 750 topological modules in the network. For this K-means clustering procedure, we stepwise increased K = 50 to 1,000 and observed the optimal K = 750 under the minimum Silhouette criterion (s = 0.1895). Among the 750 topological clusters, 40 encompassed at least one gene/protein identified by HEAL. We used the breadth-first algorithm to compute the shortest path distances between nodes in the network.
Molecular characterization of the network
We used all samples to train the genome-based model for AAA, and identified 60 genes in this disease for further functional characterization. We used Enrichr and BiNGO to determine functional enrichment for a given gene set based on Gene Ontology and Human Phenotype Ontology. For transcriptome analysis in human aortic tissues, we retrieved the published microarray data from GEO: GSE57691. We averaged the signals for multiple probe sets mapped onto the same gene. For each gene, we separately computed its mean expression across case samples (the small and large aorta groups) and control samples, and then calculated the fold change of each gene relative to the control experiment in the small and large aorta groups, respectively. The calculation of fold change was based on SAM (Significance Analysis of Microarrays). Statistical comparison was determined by the Wilcoxon ranksum test between the HEAL genes and the 17,443 human protein-coding genes as a background from which the 60 HEAL genes were selected. For the mouse transcriptome analysis, microarray signals from multiple genomic loci mapped onto the same gene were averaged. For each gene, its mean expression was calculated by averaging replicate samples in the same condition, followed by fold change calculation against the control experiments. Human genes were mapped onto their unambiguous one-to-one mouse orthologs based on Ensembl Biomart annotation (as of Feb, 2017) . Fold changes were compared for each of the 40 AAA-associated modules (encompassing the 60 AAA genes from HEAL) against the rest of the genes on the network, and the derived P values for the 40 modules were corrected by the Benjamini-Hochberg procedure. We considered statistical significance with a false discovery rate under 0.1.
QUANTIFICATION AND STATISTICAL ANALYSIS
Performance evaluation of prediction models We implemented 1,000 times 10-fold cross-validation to evaluate the performance of the genome-and EHR-based models, as well as the integrated model by aggregating both. To determine the statistical significance of the performance difference between models, we performed Wilcoxon rank-sum test on the AUROCs from the 1,000 simulations described above. In the analysis of false predictions, for each study participant, his/her prediction score was derived by averaging the scores from the 1,000 iterated crossvalidations (i.e., 1,000 times of blind testing).
To determine the association between the AAA-associated genes identified by HEAL and the EHR-recorded phenotypes, we regressed (for continuous traits) or classified (for dichotomous traits) each of the 14 EHR traits with the rare variants in AAA-associated genes. We followed exactly the same procedure as described above for the AAA analysis but replaced the AAA status with individual EHR phenotypes as the response variable. No statistically significant association with the AAA genes was observed across all the EHR traits, except for diastolic blood pressure. Despite its statistical significance, genetic variance in the AAA genes only had a moderate correlation with diastolic blood pressure with Spearman's coefficient R = 0.17, suggesting that $2.8% of the variance in diastolic blood pressure could be accounted by the variance of the AAA-associated genes (R 2 ). Therefore, to a large extent, the genome-and the EHR-based models predicted AAA from different angles.
We tested the complementarity between the genome-and EHR-based models, and specifically asked whether false predictions from personal genomes could be captured by EHR-based predictions. We first identified false positives and false negatives from personal genome predictions, and then asked how many of them were correctly captured by the EHR-based predictions: i.e., false positives in the genome model were in fact true negatives in the EHR model, or false negatives in the genome model were true positives in the EHR model. To determine statistical significance, we randomly permuted the AAA labels for EHR predictions for 1,000 times and observed that the false negatives from genome prediction were indeed enriched for the true positive predictions in the EHR model (p < 1e-3, Group 1), and it was also the case for the genome false positives in the EHR true negatives (p < 1e-3, Group 2). The identification of false positives and negatives was based on the prediction score threshold at 0.5, and the prediction scores were the average from the 1,000 iterated cross-validations.
Sensitivity (true positive rate) and specificity (true negative rate) for each prediction model was determined by the average value from the 1,000 iterated cross-validations, which were then compared with the performance of many other widely used clinical tests (Maxim et al., 2014) Simulating disease risks by altering HDL levels We performed a simulation study to illustrate the interplay between personal genome baseline and lifestyles in determining disease risk for a given individual. For individuals in this AAA cohort, we quantified their disease risk increase or decrease from their existing disease status by only in silico increasing or decreasing their plasma high-density lipoprotein (HDL) levels, whose increase has been unequivocally associated with a reduced AAA occurrence (Torsney et al., 2012) . We chose HDL for the purpose of proof-of-principle, and the same analysis could be executed on other lifestyle elements or physiological parameters. We first determined the population range (L) of the HDL levels in this cohort, which is the difference between the population maximum and the minimum. For each subject, we then step-wide increased the HDL level by 25% of L from their original EHR-recorded value until reaching the population maximum, or decreased the HDL level by 25% of L until the population minimum. Note that by altering HDL, the fraction of HDL in total cholesterol will also be changed in our regression model. With the trained integrated model by aggregating personal genomes and EHRs, AAA prediction scores were re-estimated upon the HDL changes. For each individual, the personal genome baseline was estimated based on the prediction scores from the genome-based model.
DATA AND SOFTWARE AVAILABILITY
Data access: http://med.stanford.edu/gbsc/vapahcs/va-news-.html. Whole genome sequencing data reported in this paper can be found at https://storage.google.com/gaaa0531180229.
